Cardiff Oncology Inc (CRDF)

$3.20 +0.04 (1.27%)
Market Cap 210.22M
Revenue (ttm) 680,000.00
Net Income (ttm) -45.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,680.88%
Debt to Equity Ratio 0.00
Volume 1,077,100
Avg Vol 1,113,884
Day's Range N/A - N/A
Shares Out 66.53M
Stochastic %K 17%
Beta 1.61
Analysts Strong Sell
Price Target $12.67

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 952 7570
Address:
11055 Flintkote Avenue, San Diego, United States
Slowroast1
Slowroast1 Jun. 25 at 3:03 AM
$CRDF Jeffries analyst that set his price target at 3.50 has a 17.5% success rate and negative -22% return on his previous predictions in the space. Not sure why anybody gives two shits about a price target by someone who is wrong 4 out of 5 times.
1 · Reply
Carmen_27
Carmen_27 Jun. 24 at 10:40 PM
$CRDF that ain’t Jeffries Report, that’s that got dam lochness monster again
2 · Reply
look2theblue
look2theblue Jun. 24 at 9:03 PM
$CRDF Easy money to be on the short side here, it's not going higher.
1 · Reply
look2theblue
look2theblue Jun. 24 at 9:03 PM
$CRDF Time to short more my friends!
1 · Reply
UFOsrreal
UFOsrreal Jun. 24 at 6:55 PM
$CRDF hey I want to say many say, don’t listen to people on these boards. You know it’s probably true to a certain extent, but I learn a lot here I also know a lot, but no one is perfect
1 · Reply
stevelue
stevelue Jun. 24 at 6:47 PM
$CRDF wants to bust out here...Lets Crank up the volume Whales!
0 · Reply
aaronr
aaronr Jun. 24 at 5:49 PM
$CRDF Another interesting thing I was recently looking at is depth of response as a metric. I found this paper that talked about that metric for the tribe study and then calculated it for each arm. Onvan is nearly doing the same as folfoxiri + bev with 3/11 patients only having one scan and 4/11 only having 2. Folfoxiri is what I view as the worst case minimum level of efficacy required for approval. Based on this I think it will blow it out the water as among this group of patients the metric can only improve, and I think it will likely do so pretty significantly.
2 · Reply
aaronr
aaronr Jun. 24 at 4:09 PM
$CRDF I posted a few tweets taking down the Jeffries report. After looking at it, I think he wrote this report to shake weak hands and allow clients that are short to more easily cover. https://x.com/AaronRosenblum5/status/1937543059337584987
3 · Reply
biohuntress
biohuntress Jun. 24 at 4:07 PM
$CRDF he doesn't take into account pts that may have left for potential curative surgeries.....if that number jumps substantially it can supersede durability in importance JMO....."Jefferies projects that meaningful durability data will likely not emerge until 2026, which could represent a potential inflection point for the company, and plans to reassess its rating following the July 29 data update."
0 · Reply
Thunderandlightning
Thunderandlightning Jun. 24 at 3:36 PM
$CRDF Insiders made large purchases for themselves and family after the December results. Insider buying and % ownership speaks volumes. Probably more buying after July 29th.
1 · Reply
Latest News on CRDF
Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:39 PM EDT - 7 days ago

Cardiff Oncology Names Roger Sidhu as Medical Chief

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Jun 17, 2025, 4:05 PM EDT - 7 days ago

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Jun 2, 2025, 4:05 PM EDT - 22 days ago

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

May 14, 2025, 9:05 AM EDT - 5 weeks ago

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 6 weeks ago

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

May 2, 2025, 3:35 AM EDT - 7 weeks ago

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Apr 23, 2025, 4:05 PM EDT - 2 months ago

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2025, 4:10 PM EDT - 2 months ago

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Apr 15, 2025, 4:05 PM EDT - 2 months ago

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:10 PM EST - 4 months ago

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Feb 27, 2025, 4:05 PM EST - 4 months ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 24, 2025, 4:05 PM EST - 4 months ago

Cardiff Oncology to Present at Upcoming Investor Conferences

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Feb 20, 2025, 4:05 PM EST - 4 months ago

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Feb 18, 2025, 9:19 AM EST - 4 months ago

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

Dec 14, 2024, 9:00 AM EST - 6 months ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

UI VOD DE ESPR FLNC GASS HII

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Dec 12, 2024, 5:38 AM EST - 6 months ago

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Dec 10, 2024, 5:05 PM EST - 7 months ago

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Dec 10, 2024, 7:20 AM EST - 7 months ago

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Dec 10, 2024, 6:00 AM EST - 7 months ago

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Oct 30, 2024, 4:30 PM EDT - 8 months ago

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Oct 4, 2024, 1:10 PM EDT - 9 months ago

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Aug 12, 2024, 2:57 PM EDT - 11 months ago

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 11:18 AM EDT - 11 months ago

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

Cardiff Oncology to Present at the Jefferies Healthcare Conference

May 29, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at the Jefferies Healthcare Conference

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

May 21, 2024, 11:22 PM EDT - 1 year ago

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 13, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences in May

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

May 3, 2024, 1:30 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

May 2, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 8, 2024, 7:37 PM EST - 1 year ago

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Mar 6, 2024, 4:05 PM EST - 1 year ago

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 8:06 PM EST - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Feb 29, 2024, 4:07 PM EST - 1 year ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Feb 29, 2024, 4:06 PM EST - 1 year ago

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Feb 29, 2024, 4:05 PM EST - 1 year ago

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Feb 26, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Feb 22, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Jan 17, 2024, 10:30 AM EST - 1 year ago

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 4:05 PM EST - 1 year ago

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 9:11 PM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

Oct 26, 2023, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

Costco share fall following results, while Cardiff Oncology and MillerKnoll shares soar, and more moving stocks

Sep 27, 2023, 5:56 AM EDT - 1 year ago

Costco share fall following results, while Cardiff Oncology and MillerKnoll shares soar, and more moving stocks

COST MLKN PRGS TRUE

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Sep 26, 2023, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Cardiff Oncology to Present at Upcoming Investor Conferences in September

Sep 5, 2023, 8:00 AM EDT - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences in September

Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update

Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

Aug 7, 2023, 4:05 PM EDT - 2 years ago

Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update

May 4, 2023, 4:10 PM EDT - 2 years ago

Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update

Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer

Mar 28, 2023, 8:00 AM EDT - 2 years ago

Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer

Slowroast1
Slowroast1 Jun. 25 at 3:03 AM
$CRDF Jeffries analyst that set his price target at 3.50 has a 17.5% success rate and negative -22% return on his previous predictions in the space. Not sure why anybody gives two shits about a price target by someone who is wrong 4 out of 5 times.
1 · Reply
Carmen_27
Carmen_27 Jun. 24 at 10:40 PM
$CRDF that ain’t Jeffries Report, that’s that got dam lochness monster again
2 · Reply
look2theblue
look2theblue Jun. 24 at 9:03 PM
$CRDF Easy money to be on the short side here, it's not going higher.
1 · Reply
look2theblue
look2theblue Jun. 24 at 9:03 PM
$CRDF Time to short more my friends!
1 · Reply
UFOsrreal
UFOsrreal Jun. 24 at 6:55 PM
$CRDF hey I want to say many say, don’t listen to people on these boards. You know it’s probably true to a certain extent, but I learn a lot here I also know a lot, but no one is perfect
1 · Reply
stevelue
stevelue Jun. 24 at 6:47 PM
$CRDF wants to bust out here...Lets Crank up the volume Whales!
0 · Reply
aaronr
aaronr Jun. 24 at 5:49 PM
$CRDF Another interesting thing I was recently looking at is depth of response as a metric. I found this paper that talked about that metric for the tribe study and then calculated it for each arm. Onvan is nearly doing the same as folfoxiri + bev with 3/11 patients only having one scan and 4/11 only having 2. Folfoxiri is what I view as the worst case minimum level of efficacy required for approval. Based on this I think it will blow it out the water as among this group of patients the metric can only improve, and I think it will likely do so pretty significantly.
2 · Reply
aaronr
aaronr Jun. 24 at 4:09 PM
$CRDF I posted a few tweets taking down the Jeffries report. After looking at it, I think he wrote this report to shake weak hands and allow clients that are short to more easily cover. https://x.com/AaronRosenblum5/status/1937543059337584987
3 · Reply
biohuntress
biohuntress Jun. 24 at 4:07 PM
$CRDF he doesn't take into account pts that may have left for potential curative surgeries.....if that number jumps substantially it can supersede durability in importance JMO....."Jefferies projects that meaningful durability data will likely not emerge until 2026, which could represent a potential inflection point for the company, and plans to reassess its rating following the July 29 data update."
0 · Reply
Thunderandlightning
Thunderandlightning Jun. 24 at 3:36 PM
$CRDF Insiders made large purchases for themselves and family after the December results. Insider buying and % ownership speaks volumes. Probably more buying after July 29th.
1 · Reply
stevelue
stevelue Jun. 24 at 3:29 PM
$CRDF
0 · Reply
Huber65
Huber65 Jun. 24 at 3:06 PM
$CRDF everyone is forgetting also that institutions do believe in this stock. Have gone this year from maybe less then 15 percent ownership to over 55 percent last we know. This is huge. This is a manipulated stock , but once good data is released , manipulation will be gone and institutions will reap the reward
1 · Reply
Core366
Core366 Jun. 24 at 2:31 PM
$CRDF How tf do you know what the cr004 data reads? Literally twll us you are short without telling us.
2 · Reply
DD_investments
DD_investments Jun. 24 at 1:51 PM
$CRDF price targets don’t mean shit in bio, whether they’re high or low. All that matters is that the data come July 29 is in line with the data from December 2024
1 · Reply
McGinvests
McGinvests Jun. 24 at 1:48 PM
$CRDF lol the pumpers here are a joke. Price analyst says $20 and everyone praises them. Now they say $3.50 and everyone says price analysts are wrong 😂 don’t listen to anyone here. All talking out their ass
3 · Reply
Core366
Core366 Jun. 24 at 1:40 PM
$CRDF This is from 2023 , short tard
2 · Reply
AP1810
AP1810 Jun. 24 at 1:07 PM
$CRDF https://www.oncologypipeline.com/apexonco/another-twist-cardiffs-onvansertib-plan?utm_source=chatgpt.com scary read…
4 · Reply
rag2riches
rag2riches Jun. 24 at 12:58 PM
$CRDF humbling price target and rating, but i never paid much attention to them. Ill have to read the report whenever it crosses my lap. Going to be a long time until July 29th. Enjoy the summer while its still here
1 · Reply
Chuck_M
Chuck_M Jun. 24 at 12:45 PM
$CRDF Jefferies Analyst Maury Raycroft Maury Raycroft is a Wall Street analyst working for Jefferies, with a focus on the General sector and covering 70 stocks with a 36.96% success rate. He has covered 29 stocks with a 17.5% success rate and an average return of -22.94%.
2 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jun. 24 at 12:31 PM
$CRDF Jefferies Initiates Coverage On Cardiff Oncology with Hold Rating, Announces Price Target of $3.5
2 · Reply
JarvisFlow
JarvisFlow Jun. 24 at 12:30 PM
Jefferies has updated their rating for Cardiff Oncology ( $CRDF ) to Hold with a price target of 3.5.
1 · Reply
Huber65
Huber65 Jun. 24 at 11:51 AM
$CRDF coverage is most important thing . We all know how useless target prices are and how fast they can be lowered or raised
1 · Reply